CNP-PLP139-151

CNP-PLP139-151 is a tolerogenic immune-modifying nanoparticle (TIMP) developed by Cour Pharmaceutical Development Company. It consists of biodegradable poly(d,l-lactic-co-glycolic acid) (PLGA) nanoparticles, approximately 400-800 nm in diameter, that encapsulate the myelin proteolipid protein (PLP) peptide fragment 139-151. Designed for the treatment of multiple sclerosis, the drug functions by inducing antigen-specific immune tolerance. Following intravenous administration, the nanoparticles are selectively captured by MARCO-expressing macrophages in the splenic marginal zone and liver. Phagocytosis of the particles induces myeloid cell apoptosis, which triggers the cGAS/STING pathway via the generation of oxidized DNA (8-OHG). This activation leads to local type I interferon (IFN) production and the expansion of antigen-specific FoxP3+ regulatory T cells (Tregs) and Tr1 cells, effectively suppressing the autoimmune response against myelin without causing systemic immunosuppression.

Other names

PLP139-151-encapsulating PLGA nanoparticlesPLP-139-151-encapsulating PLGA nanoparticlesPLP 139-151-encapsulating PLGA nanoparticlesCour nanoparticles PLP139-151